Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | CA1 | P00915 | 3/20 | 0.58 |
| ▸ | CA2 | P00918 | 3/20 | 0.58 |
| ▸ | CA12 | O43570 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | CA7 | P43166 | 2/20 | 0.58 |
| ▸ | CA4 | P22748 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.57 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | MTOR | P42345 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 2/20 | 0.52 |
| ▸ | FPR2 | P25090 | 1/20 | 0.50 |
| ▸ | CCR3 | P51677 | 2/20 | 0.48 |
| ▸ | GOT1 | P17174 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23328398 | 0.97 | MEN1 (0.63) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL23328404 | 0.92 | MEN1 (0.67) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL28728293 | 0.87 | MEN1 (0.77) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL23328370 | 0.86 | MEN1 (0.60) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL23328405 | 0.85 | SMN1; SMN2 (0.67) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL23328393 | 0.83 | SMN1; SMN2 (0.68) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL23328365 | 0.82 | FPR2 (0.67) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL23329071 | 0.82 | MEN1 (0.61) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL20681685 | 0.81 | MEN1 (0.68) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL25841056 | 0.80 | MEN1 (0.67) | MEN1KMT2ACA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701333-B2 | Antibacterial compounds | Kent Innovation & Enterprise (GB) | 2023-07-18 | — | — | US | disclosed |
| US-20210128501-A1 | ANTIBACTERIAL COMPOUNDS | KENT INNOVATION & ENTERPRISE, UNIVERSITY OF KENT (GB) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701333-B2 | Antibacterial compounds | ARF1, ARL1, TLR1 | MEN1 1300/4885KMT2A 2533/4885CA1 4609/4885 |
| US-20210128501-A1 | ANTIBACTERIAL COMPOUNDS | ARF1, ARL1, TLR1 | MEN1 1300/4885KMT2A 2533/4885CA1 4609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.